Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSource International

This article was originally published in The Gray Sheet

Executive Summary

Manufacturer of immunological reagents, test kits and oligonucleotides for biomedical research withdraws planned follow-on offering of 4 mil. shares "due to recent market conditions," the firm announces May 4. The Camarillo, California company had filed a registration statement for the offering with the Securities and Exchange Commission on March 22 (1"The Gray Sheet" April 3, p. 22)

You may also be interested in...



BioSource International

Manufacturer of immunological reagents, test kits and oligonucleotides for biomedical research plans follow-on offering of 4 mil. shares of common stock, of which 650,000 are being offered by selling shareholders. Proceeds are tabbed for "future acquisitions," R&D, working capital and general corporate purposes. Underwriters are Chase H&Q, Dain Rauscher Wessels, and Thomas Weisel Partners. The Camarillo, California firm reports 1999 sales of $29.3 mil., up 33.8%. Net income of $3.6 mil. compares to a net loss of $5.1 mil. in 1998

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

UsernamePublicRestriction

Register

MT013324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel